Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Liabilities and Shareholders Equity of $1.2 billion for Q1 2026, up 3.26% quarter-over-quarter from $1.1 billion in Q4 2025.
Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
Caris Life Sciences' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 1129.93% YoY), while the FY2025 annual figure was $1.1 billion, up 227.48% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.2 billion in Q1 2026, with the low at $343.7 million in Q4 2024.
- The 3-year median for Liabilities and Shareholders Equity is $984.6 million (2025), against an average of $914.3 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 227.48% in 2025, while the deepest fall reached 227.48% in 2025.
- Caris Life Sciences' Liabilities and Shareholders Equity stood at $343.7 million in 2024, then surged by 227.48% to $1.1 billion in 2025, then grew by 3.26% to $1.2 billion in 2026.
- Business Quant data shows CAI's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $984.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 1.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Bn |
| Mar 31, 2026 | 1.16 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 984.57 Mn |
| Jun 30, 2025 | 955.06 Mn |
| Dec 31, 2024 | 343.73 Mn |